Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 8/20 | 0.42 |
| ▸ | FPR3 | P25089 | 7/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962327 | 0.86 | CNR2 (0.53) | EPHX2CNR1CNR2 | |
| SCHEMBL4826893 | 0.70 | MAPK10 (0.46) | MAPK10SMN1; SMN2FPR2FPR3CCNE1 | |
| SCHEMBL963487 | 0.70 | CNR2 (0.53) | EPHX2CNR1CNR2 | |
| SCHEMBL20270816 | 0.69 | SMN1; SMN2 (0.58) | MAPK10SMN1; SMN2FPR2FPR3CCNE1 | |
| SCHEMBL6729 | 0.68 | CCNE1 (0.59) | MAPK10SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL986246 | 0.68 | CNR2 (0.42) | ADORA1P2RX7EPHX2CNR1CNR2 | |
| SCHEMBL14476229 | 0.67 | SMN1; SMN2 (0.55) | MAPK10SMN1; SMN2FPR2FPR3CCNE1 | |
| SCHEMBL1749806 | 0.67 | SMN1; SMN2 (0.59) | MAPK10SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL963181 | 0.67 | CNR1 (0.50) | EPHX2CNR1CNR2 | |
| SCHEMBL4093014 | 0.66 | CNR2 (0.55) | ADORA1P2RX7CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024349-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-9006275-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20110086855-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7875639-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ADORA1 109/4885P2RX7 101/4885EPHX2 398/4885 |
| US-20110086855-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | ADORA1 109/4885P2RX7 101/4885EPHX2 398/4885 |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | ADORA1 8/4885P2RX7 41/4885EPHX2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.